Adriamycin and Ifosfamide Combined With Sintilimab

Cannot have received: anti-PD-1 therapy

Patients who had previously received anti-PD-1 / PD-L1 antibody therapy

Cannot have received: anti-PD-L1 therapy

Patients who had previously received anti-PD-1 / PD-L1 antibody therapy

Cannot have received: systemic anti-tumor therapy

Systemic anti-tumor therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or mitomycin C within 6 weeks prior to the trial drug treatment) was planned within 4 weeks before enrollment or during the study period

Cannot have received: extended field radiotherapy

Over extended field radiotherapy (ef-rt) was performed within 4 weeks before admission

Cannot have received: limited field radiotherapy

limited field radiotherapy (rfrt) was performed within 2 weeks before grouping

Cannot have received: other clinical trial anti-tumor drugs

Patients who participated in other clinical trials of anti-tumor drugs within 28 days before enrollment